Untitled

[fromsciencetopharma]

Less selling, more science can best help doctors navigate complex new cancer treatments, report suggests The future of cancer drug marketing will be about helping oncologists understand the complexities of precision medicine and how new advances in targeted therapies can help their specific patients. That means drug companies will need to focus less on the selling, more on the science. And they’ll need real world data to prove their drugs work as well in the “messy setting of everyday life” as they do in the clinic, a new Accenture survey of 120 oncologists in the U.S. and Germany suggests. “The clinical trials that are the basis for your promotional materials – those are just your ticket to play,” said André T. Dahinden, a managing director of global precision oncology in Accenture’s Life Sciences division. Oncologists are asking, “What do these medicines really do in reality?” With the number of cancer drugs and drug combinations growing exponentially, it’s less likely a single sales rep can answer all of a doctor’s questions, said Dahinden. The need for more scientific guidance is especially true for community practice oncologists, who are working outside the realm of specialized cancer centers, he added.” https://lnkd.in/guVFUQGr #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #PHD #postdoc #pharmaceuticals #medicalaffairs #postdoc #pharma #pharmacy #clinicalresearch https://www.instagram.com/from_science_to_pharma/p/CZGjXXwJSfV/?utm_medium=tumblr

[fromsciencetopharma]

Hallmarks of Cancer: New Dimensions The review everyone is reading right now... An updated perspective on the "Hallmarks of Cancer" from Douglas Hanahan. In the review the author introduces new hallmarks and enabling characteristics of cancer: “unlocking phenotypic plasticity,” “nonmutational epigenetic reprogramming,” “polymorphic microbiomes,” and “senescent cells” https://lnkd.in/d4yc2a4w #cancerresearch #cancer #oncology #science #MSL #fstp #medicalaffairs #medicalscienceliaison #BoardcertifiedMSL #bcmslcert https://www.instagram.com/p/CYvyseIp0Kl/?utm_medium=tumblr

[fromsciencetopharma]

Oxford joins consortium to advance quantum drug discovery #drugdiscovery #quantumcomputing “The partnership between Oxford University and SEEQC promises to accelerate the use of quantum computing within pharmaceutical research in order to reduce the development time required for drug production worldwide. Oxford University has joined a consortium led by the digital quantum computing company, SEEQC, to build and deliver a full-stack quantum computer for pharmaceutical drug development for Merck KGaA. The consortium has been awarded a £6.85m grant, by Innovate UK’s Industrial Strategy Challenge Fund (ISCF) to build a commercially scalable quantum computer designed to tackle prohibitively high costs within pharmaceutical drug development. it is an opportunity for us to work with so many technology leaders and potentially transform the process of drug discovery. We must make it better, faster and cheaper.” The news marks the first time a quantum computer has been integrated with a high-performance computer in the same network infrastructure. The quantum computer will require a redesigned refrigerator to support cooling at multiple levels, specifically for the cryogenic decoder.” #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #PHD #postdoc #pharmaceuticals #medicalaffairs #postdoc #pharma #pharmacy #clinicalresearch #pharmaindustry #biopharma #biotech #pharmaceuticalindustry #academia https://lnkd.in/e7Ruaasm https://www.instagram.com/p/CYnFI_HhMQc/?utm_medium=tumblr

[fromsciencetopharma]

2021 drug approvals: In a year dominated by COVID, biopharma managed to deliver 55 new drugs #fdaapproval #MSL #FSTP #BoardcertifiedMSL #BCMSLcert “Each year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. With the COVID-19 crisis stretching into its third year, the 2021 batch of new drug approvals clearly demonstrates that the sector has learned how to operate in a pandemic. All told, the industry nabbed 55 FDA approvals in 2021. They include the controversial accelerated approval for Biogen's Alzheimer's drug Aduhelm, Pfizer's record-shattering COVID-19 vaccine, Comirnaty, and many others. Not all 2021 approvals commanded as many headlines as Aduhelm and Comirnaty. Aside from those notable companies, also represented in 2021's crop of new approvals were Amgen, Bristol Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck and Regeneron. And among the dozens of new drugs green-lit last year, companies such as BridgeBio, ChemoCentryx and Apellis won their first-ever FDA approvals, setting them up to make their commercial debuts. RELATED: FDA missing more approval target dates as COVID slows inspections Yet, some applications did face pandemic challenges. The FDA struggled to keep up with its inspection duties during the pandemic, leading to regulatory delays for certain drugmakers. In November, the agency reported that 55 new drug applications were facing inspection delays. Avadel Pharmaceuticals and UCB were among those to experience inspection-related delays in 2021. “ 2021 drug approvals: In a year dominated by COVID, biopharma managed to deliver 55 new drugs 1. #Verquvo 2. #Cabenuva 3. #Lupkynis 4. #Tepmetko 5. #Ukoniq 6. #Breyanzi 7. #Evkeeza 8. #Cosela 9. Amondys 45 10. #Pepaxto 11. #Nulibry 12. #Azstarys 13. #Fotivda 14. #Ponvory 15.#Zegalogue 16. #Abecma 17. #Qelbree 18. #Nextstellis 19. #Jemperli 20. #Zynlonta 21. #Empaveli 22. #Rybrevant 23. #Lybalvi 24. #Truseltiq 25. #Lumakras … https://lnkd.in/gwV7JXXe https://www.instagram.com/p/CYVaOqVpos3/?utm_medium=tumblr

[fromsciencetopharma]

Leo Pharma gains FDA nod for eczema drug Adbry, but can it challenge Sanofi and Regeneron's formidable Dupixent? #eczema #fdaapproval #leopharma “Hoping to cut into the dominance of Dupixent, Leo Pharma of Denmark has gained FDA approval for Adbry (tralokinumab) as a treatment for moderate to severe atopic dermatitis. The injected antibody drug is for adults 18 and older who don’t get adequate relief from topical prescription therapies. It can be used in combination with topical cortiocosteroids. Leo obtained tralokinumab from AstraZeneca for $115 million in 2016. The drug, which inhibits the IL-13 cytokine, was originally developed to treat asthma. Sanofi and Regeneron’s Dupixent, an injected drug which simultaneously inhibits the IL-13 and IL-4 cytokines, was approved for eczema (atopic dermatitis) in 2017 and asthma in 2018.” Interested to work in the field of Dermatology as an MSL? Several MSL roles are soon to be advertised on this therapeutic area. Time to reach out to the HR team or the company hiring manager and upskill on your disease knowledge. https://lnkd.in/e6dtadE #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #PHD #postdoc #pharmaceuticals #medicalaffairs #postdoc #pharma #pharmacy #clinicalresearch #pharmaindustry #biopharma #biotech https://lnkd.in/gQKW_MkE https://www.instagram.com/p/CYPquonBUmF/?utm_medium=tumblr

[fromsciencetopharma]

Biogen's roller coaster 2021 takes another surprising turn with report of $42B Samsung buyout interest #Biogen #samsung “Samsung Group is in talks to buy Biogen in a deal that could be worth $42 billion, the Korea Economic Daily reported Wednesday, citing investment banking sources. If the report is true—and if negotiations succeed—Samsung would take control of Biogen at a time when the biotech is laboring to launch its controversial Alzheimer’s drug, Aduhelm, and suffering from declining revenues as generics eat away sales of its flagship multiple sclerosis drug, Tecfidera. Reports of the potential buyout sent Biogen shares soaring Wednesday afternoon, from $235 per share up to $262.40 at press time. That’s still far below what the stock was worth back in June, just after Aduhelm’s approval, when it was trading above $400 per share.” #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #PHD #postdoc #pharmaceuticals #medicalaffairs #postdoc #pharma #pharmacy #clinicalresearch https://lnkd.in/dAVBsKec https://www.instagram.com/p/CYPpbhABTsR/?utm_medium=tumblr

[fromsciencetopharma]

Upskilling for aspiring MSL wanting to break into the Onvology space #MSL #Oncology #upskilling Chemotherapeutic agents, also referred to as antineoplastic agents, are used to directly or indirectly inhibit the uncontrolled growth and proliferation of cancer cells. They are classified according to their mechanism of action and include alkylating agents, antimetabolites, topoisomerase inhibitors, antibiotics, mitotic inhibitors, and protein kinase inhibitors. Chemotherapy is associated with a range of adverse effects (e.g., nausea, vomiting, immunosuppression, and impaired growth of healthy cells), and some agents increase the risk of secondary neoplasm development. Interested to work in the field of Oncology as an MSL? Several MSL roles are soon to be advertised on this therapeutic area. Time to reach out to the HR team or the company hiring manager and upskill on your disease knowledge. https://lnkd.in/e6dtadE #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #PHD #postdoc #pharmaceuticals #medicalaffairs #postdoc #pharma https://lnkd.in/g8VjgGM2 https://www.instagram.com/p/CYNTea-h6Q2/?utm_medium=tumblr

[fromsciencetopharma]

Girding for BMS competition, Amgen wins another plaque psoriasis nod for Otezla #psoriasis “As Amgen’s Otezla girds for competition against a potentially formidable rival, the company is doing all it can to gain an edge for the plaque psoriasis treatment. On Monday, Otezla nabbed an FDA approval that expands its use to those who are candidates for phototherapy or systemic therapy. The indication, for the milder version of the disorder, now makes Otezla the only oral treatment sanctioned all severities of plaque psoriasis—mild, moderate and severe. It also brings roughly 1.5 million potential patients into the fold. Earlier this month, Amgen set itself up for perhaps another FDA nod for Otezla. The company said its treatment was effective against moderate to severe genital psoriasis, a condition which effects up to 63% of psoriasis patients. Tuesday’s approval was based on findings from a phase 3 trial in which five times as many adults with mild to moderate plaque psoriasis receiving Otezla twice daily achieved the primary endpoint of static physician’s global assessment response at week 16 compared to placebo.” #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #PHD #postdoc #pharmaceuticals #medicalaffairs #postdoc #pharma https://lnkd.in/gMErDJ4Q https://www.instagram.com/p/CXw_ByNBVqS/?utm_medium=tumblr

[fromsciencetopharma]

Vaccines still provide ‘significant protection’ against severe COVID-19 #covid19research “Omicron has been the latest variant to test the effectiveness of COVID-19 vaccines. COVID-19 vaccines appear to have become less effective in preventing severe COVID-19 disease and death, but they still provide ‘significant protection’, says the World Health Organisation (WHO), according to Reuters. The Omicron variant, first detected in South Africa and Hong Kong last month, has now been reported by 77 countries. WHO director general Tedros Adhanom Ghebreyesus emphasised that it should not be dismissed as “mild”. “Omicron is spreading at a rate we have not seen with any previous variant,” Tedros told an online briefing. “Even if Omicron does cause less severe disease, the sheer number of cases could once again overwhelm unprepared health systems. Evolving evidence suggests a small decline in the effectiveness of vaccines against severe disease and death, and a decline in preventing mild disease or infection.” Tedros added that vaccine booster shots can play an important role in curbing the spread of Omicron, as long as people most in need of protection receive access to jabs.” While there is still further evidence needed to evaluate whether Omicron is less harmful than Delta, current hospitalisation rates indicate that the new variant is causing fewer infections. The NHS is still facing the threat of becoming overwhelmed in the coming months due to the alarming rate at which Omicron is rising.” #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #PHD #postdoc #pharmaceuticals #medicalaffairs #postdoc #pharma #pharmacy #clinicalresearch https://lnkd.in/ep2gsSfe https://www.instagram.com/p/CXj1VxtBSkK/?utm_medium=tumblr

[fromsciencetopharma]

Study finds Omicron multiplies 70 times faster than Delta, UK COVID-19 cases exceed 75,000 #covid19pandemic #omicronvariant “A study run by researchers in Hong Kong has found that the Omicron variant of COVID-19 multiplies 70 times faster than Delta in human airways. However, the virus was seen to replicate less rapidly than the original strain of the virus in human lung tissue, potentially indicating a lower severity of the disease. Dr Michael Chan Chi-Wai, the professor who lead the research, warned that it was important to note that “by infecting many more people, a very infectious virus may cause more severe disease and death even though the virus itself may be less pathogenic”. The research arrives as the head of UK Health Security Agency, Dr Jenny Harries, has warned MPs that the Omicron variant is “probably the most significant threat” since the start of the pandemic. Harries told MPs to expect “staggering” rates of confirmed cases over the coming days.” #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #PHD #postdoc #pharmaceuticals #medicalaffairs #postdoc #pharma https://www.instagram.com/p/CXj0iYbhyst/?utm_medium=tumblr

[fromsciencetopharma]

European Commission approves Pfizer’s atopic dermatitis treatment #pfizer #atopicdermatitis #ema “The approval from the European Commission (EC) is based on the results of five clinical studies, involving over 2,800 patients. The European Commission has approved the 100mg and 200mg doses of Cibinqo (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. A 50mg dose has also been approved to treat moderate-to-severe atopic dermatisis, specifically in patients with moderate and severe renal impairment (kidney failure), or certain patients receiving treatment with inhibitors of cytochrome P450 (CYP) 2C19. This EC approval was based on the results of five clinical studies, including four phase 3 studies and an ongoing long-term open label extension study. These studies included over 2,800 patients and Cibinqo demonstrated meaningful improvements across measures of symptom relief and disease control versus placebo.” Interested to work in the field of #dermatology as an MSL? Several MSL roles are soon to be advertised on this therapeutic area. Time to reach out to the HR team or the company hiring manager and upskill on your disease knowledge. https://lnkd.in/e6dtadE #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #PHD #postdoc #pharmaceuticals #medicalaffairs #postdoc #pharma https://lnkd.in/e5mZpd8r https://www.instagram.com/p/CXb_fPVBN9V/?utm_medium=tumblr

[fromsciencetopharma]

ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payload targets mediate polyclonal acquired clinical resistance to #ADC #cancerresearch #cancercare https://lnkd.in/eAJNFnym https://www.instagram.com/p/CXUi1YKhE6F/?utm_medium=tumblr

[fromsciencetopharma]

Cancer clinical trial recruitment drops by 60% during pandemic #Cancertrials #clinicaltrials #pandemic “In a new report from The Institute of Cancer Research (ICR), data from cancer trials alongside assessments from clinicians and patients aims to provide guidance on how to improve services The number of cancer patients entering clinical trials has fallen drastically during the pandemic, creating a barrier in accessing treatment options, and delaying the development of innovative drugs and technologies, according to Hospital Pharmacy Europe. The ICR, London, is publishing a report containing data from cancer trials and the views of patients and clinicians on how to overcome challenges in making trials more widely available. Extending the availability and access to clinical trials for patients is of increasing need, in order to avoid missing important opportunities to drive improvements in treatment options. The National Institute for Health Research has reported that the number of patients recruited onto clinical trials for cancer in England fell to 27,734 in 2020/21, down from an average of 67,057 over the previous three years. The number of patients recruited onto trials also fell for almost every type of cancer analysed.” #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #PHD #postdoc #pharmaceuticals #medicalaffairs #postdoc #pharma #pharmacy #clinicalresearch https://lnkd.in/dQ2yqkQV https://www.instagram.com/p/CXRuyc8BTDQ/?utm_medium=tumblr

[fromsciencetopharma]

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO. #ESMO #Oncology A pretty cool tool for anyone working in Oncology in Europe or following the ESMO recommendation. The ESMO-MCBS Scorecards The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.” #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #PHD #postdoc #pharmaceuticals #medicalaffairs #postdoc #pharma https://lnkd.in/dDmWN3Yg https://www.instagram.com/p/CXRuUsohsMa/?utm_medium=tumblr

[fromsciencetopharma]

GSK to provide malaria vaccines for Gavi eligible countries #GSK #malaria #greatnews “This follows the World Health Organisation’s (WHO) recommendation for the broader use of GSK’s RTS,S/AS01e to combat the issue of childhood illness and deaths from malaria in children living in sub-Saharan Africa and other regions with moderate to high transmission, as defined by WHO. The new development will arm healthcare providers with a vital tool to address the steep rise of malaria cases in children living in Africa. Africa continues to have the heaviest malaria burden and African children are at highest risk of dying of malaria. Over 260,000 African children under the age of five died from malaria in 2019 and COVID-19 has only exacerbated this disease burden. This highlights the ever-growing, urgent need for new and innovative tools to combat malaria. RTS,S/AS01e is the result of over 35 years of research led by GSK, with nonprofit health organisation PATH and other partners. It is the first and only malaria vaccine to have been shown in pivotal long-term clinical trials to significantly reduce malaria in children.” #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #phd https://lnkd.in/eADTdp4Z https://www.instagram.com/p/CXNh1popk9u/?utm_medium=tumblr

[fromsciencetopharma]

More growth on the way for CSL? Australian giant in talks to buy Vifor for $7.1B: report #csl #Vifor #acquisition “Australian biotech giant CSL is negotiating with Vifor Pharma Group to acquire the Swiss company for A$10 billion ($7.1 billion), says the Australian Financial Review. The acquisition would become the largest ever for CSL. The companies were in talks in March, the Australian publication reported, but the talks have now become more serious. The report comes less than six months after Abbas Hussain left the board at CSL to become the CEO of Vifor, an 88-year-old specialty pharmaceutical company. Vifor markets iron deficiency, nephrology and cardio-renal products in more than 100 countries worldwide, its website says. Addressing "market speculations" Thursday, the company said it "systematically reviews options that can strengthen its market position and/or accelerate the growth of the company both organically and through partnerships and acquisitions." CSL, which has no rivals as Australia’s largest company in the biopharma industry, has made several major acquisitions over the last few decades. Its $275 million purchase of Novartis’ flu vaccine business in 2014 help build CSL’s Seqirus into one of the top flu shot players in the world. Beyond that, its buyouts of Florida-based Nabi and Zentrallaboratorium twenty years ago helped make CSL the world’s premier plasma collection company. A $965 million buy of Aventis Behring in 2003 helped broaden CSL's product portfolio” Early this year, CSL began producing AstraZeneca’s COVID-19 vaccine. It also manufactured the University of Queensland’s investigational COVID-19 shot, until the project was discontinued. Vifor’s largest shareholder is Swiss billionaire Martin Ebner, who owns Helvetic Airlines and BZ Bank and the BZ Group.” #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #phd https://lnkd.in/eF8UdJZJ https://www.instagram.com/p/CXHgEV8Bj7l/?utm_medium=tumblr

[fromsciencetopharma]

Vertex, needing research spark, finds promising results in small study of kidney disease drug #Vertex #kidneydisease “ The biotech, which has been stung by recent clinical setbacks, plans to soon advance the medicine into late-stage testing. Vertex Pharmaceuticals will quickly advance an experimental drug for a genetic form of kidney disease into late-stage testing, after results from a small study surpassed the company's expectations. The findings are early evidence for a new way of treating the condition, called focal segmental glomerulosclerosis, by targeting gene variations first identified as significant a little more than a decade ago. They're also a much-needed win for Vertex, which, despite having successfully developed four effective drugs for cystic fibrosis, has struggled to convince investors it can repeat its success in other diseases. Focal segmental glomerulosclerosis, or FSGS, describes scarring of the kidney that impairs the organ's ability to filter blood, resulting in high levels of protein in urine. It has a range of causes, such as viral infections or drug toxicity, and is one of several ways kidney disease can develop. Patients are typically treated with blood pressure medicines and steroids, which offer limited benefit. In 2010, a group of researchers in the U.S. and Belgium discovered that two variants in a gene called APOL1 dramatically increase the risk of kidney disease, including FSGS specifically, and can lead to more aggressive progression. Though Vertex still has much to prove, two of its experimental drug programs have shown signs of promise. In October, the company reported encouraging findings from the first patient given a stem cell-based diabetes treatment. And the study results released by the company Wednesday suggest that it's on the right track with APOL1 and kidney disease as well. #MSL #FSTP #BCMSLcert #BoardCertifiedMSL #medicalscienceliaison medical science liaison #Medicalaffairs https://www.instagram.com/p/CW9HeQmhP7U/?utm_medium=tumblr